Scarica l'app Stockscreener
34.31
3.25%
1.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$33.23
Aprire:
$33.39
Volume 24 ore:
2.04M
Relative Volume:
1.35
Capitalizzazione di mercato:
$4.11B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-6.5228
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
-5.12%
1M Prestazione:
-7.30%
6M Prestazione:
-18.66%
1 anno Prestazione:
-38.93%
Intervallo 1D:
$33.17
$34.91
Intervallo di 1 settimana:
$32.89
$36.79
Portata 52W:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
34.31 | 3.98B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Is Cytokinetics Incorporated stock entering bullish territoryPrice Movement and Market Sentiment Analysis - Newser
Using Ichimoku Cloud for Cytokinetics Incorporated technicalsSafe Momentum Strategy With Trend Analysis - Newser
Citigroup Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics (NASDAQ:CYTK) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Cytokinetics and the Imminent Commercialization of Aficamten: A High-Conviction Buy Before the December 2025 FDA Decision - AInvest
Cytokinetics and the Aficamten Opportunity: Navigating FDA Delays, Strong Analyst Consensus, and High GF Value for a High-Probability Breakout in 2026 - AInvest
Cytokinetics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Pattern recognition hints at Cytokinetics Incorporated upsideTechnical Safety Zone Pattern Recognition - Newser
What candlestick patterns are forming on Cytokinetics IncorporatedFree High Yield Stock Screening Results - Newser
What indicators show strength in Cytokinetics IncorporatedFree Pattern Breakout Entry Stock Forecast - Newser
Cytokinetics 2025 Q2 Earnings Narrowed Losses Amid Revenue Surge - AInvest
Cytokinetics: Citigroup maintains Buy rating, lowers PT to $77 from $80. - AInvest
Cytokinetics shares rise 3.20% after-hours following Q2 2025 earnings call. - AInvest
Cytokinetics, Incorporated shares fall 1.56% intraday after reporting earnings and regulatory updates. - AInvest
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
Cytokinetics rises as investors await US approval for heart drug - TradingView
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat - Investing.com
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat By Investing.com - Investing.com South Africa
Navigating Financial Challenges Amid Promising Clinical Developments: Cytokinetics Inc. (CYTK) Q2 2025 Earnings Call Highlights - AInvest
Cytokinetics Q2 Loss Narrows, Revenue Rises - MarketScreener
Cytokinetics Q2 2025 Earnings Call Transcript - MarketBeat
Cytokinetics Reports Q2 2025 Financial Results and Updates - TipRanks
Cytokinetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytokinetics shares rise on strong Q2 results By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytokinetics: Q2 Earnings Snapshot - San Francisco Chronicle
CYTOKINETICS INC SEC 10-Q Report - TradingView
Cytokinetics Inc earnings beat by $0.30, revenue topped estimates - Investing.com Australia
Cytokinetics Earnings Surge: Revenue Jumps to $66.8M with FDA Decision on Key Drug Coming December - Stock Titan
ATTENTION Cytokinetics, Incorporated Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Federated Hermes Inc. Has $1.37 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
TR | OpenAI4o Initiates Cytokinetics(CYTK.US) With Hold Rating, Announces Target Price $37 - 富途牛牛
Top Executive Sells Thousands in Cytokinetics Stock! - TipRanks
Malik, Cytokinetics EVP, sells $72,680 in shares By Investing.com - Investing.com Canada
Malik, Cytokinetics EVP, sells $72,680 in shares - Investing.com India
Cytokinetics EVP Research & Development Malik Fady Ibraham Buys 2000 Shares at $10.6/Share, Sells 2000 Shares at $36.34/Share. - AInvest
Spinal Muscular Atrophy Market Opportunities and Future Scope - openPR.com
Will Cytokinetics Incorporated Recover After Recent DeclineReliable Investment Entry Signals Confirmed by Charts - beatles.ru
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by Assetmark Inc. - Defense World
Published on: 2025-08-04 22:46:47 - metal.it
Cytokinetics Incorporated Price Holds Above Key Fib LevelAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Why Cytokinetics Incorporated stock attracts strong analyst attentionSwing Entry Risk Mitigation with Chart Analysis - Newser
What are analysts’ price targets for Cytokinetics Incorporated in the next 12 monthsOutstanding capital growth - Jammu Links News
How strong is Cytokinetics Incorporated company’s balance sheetBuild a diversified portfolio for risk management - Jammu Links News
Cytokinetics Incorporated Stock Analysis and ForecastBuild wealth with long-term growth strategies - Jammu Links News
What makes Cytokinetics Incorporated stock price move sharplyCapitalize on emerging industry trends - Jammu Links News
What is Cytokinetics Incorporated company’s growth strategyMarket-leading capital gains - Jammu Links News
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Raymond James Financial - MarketBeat
What catalysts could drive Cytokinetics Incorporated stock higher in 2025Build a winning investment portfolio - Jammu Links News
Should I hold or sell Cytokinetics Incorporated stock in 2025Rapid growth opportunities - Jammu Links News
What are the latest earnings results for Cytokinetics IncorporatedExpert Picks Outlook For Beginners - jammulinksnews.com
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):